secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001493152-24-006087
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Pharma Q2 FY2024 net loss narrows to $2.7M; cash $6.6M; advancing selonabant
--------------------------------------------------------------------------------

- Net loss $2.7M ($0.11/sh) vs $3.8M ($0.15/sh) in Q2 FY2023; operating expenses $2.8M.
- Cash $6.6M at Dec 31, 2023; secured $10M credit facility from existing investors.
- Selonabant (ANEB-001) generic name adopted; IV formulation in development.
- Targeting Phase 3 study start in H1 2024; new CEO Richie Cunningham and board member Bimal Shah.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224006087/0001493152-24-006087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224006087/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-006087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer